A single center retrospective cohort study to assess adherence to biologic medications prescribed for inflammatory bowel disease and to identify risk factors for biologic nonadherence
Latest Information Update: 14 Apr 2020
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab; Certolizumab pegol; Infliximab
- Indications Crohn's disease; Inflammatory bowel diseases
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 14 Apr 2020 New trial record